Release details

2019-04-09 07:00 CEST
  • Print
  • Share Share
en nl

Biocartis Group NV: Invitation to Annual Shareholders' Meeting

PRESS RELEASE                                                                                     9 April 2019, 07:00 CEST
                                                                                                            REGULATED INFORMATION

Invitation to Annual Shareholders' Meeting

Mechelen, Belgium, 9 April 2019 - Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), has the honor to invite its shareholders, warrant holders, directors and statutory auditor to its annual shareholders' meeting that will be held on Friday 10 May 2019 at 2:00 p.m. CEST ('AGM') at the offices of the Company at Generaal de Wittelaan 11B, 2800 Mechelen, Belgium. 

In order to be admitted to the AGM, the holders of securities issued by the Company must comply with Article 536 of the Belgian Companies Code and the articles of association of the Company, and fulfill the formalities described in the convening notice. The convening notice and other documents relating to the AGM can be consulted on the website of the Company.

--- END ---

More information:

Renate Degrave
Manager Corporate Communications & Investor Relations
e-mail   rdegrave@biocartis.com
tel         +32 15 631 729
gsm      +32 471 53 60 64
@Biocartis_
www.linkedin.com/Biocartis

About Biocartis 

Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla(TM) platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology. This area represents the fastest growing segment of the MDx market worldwide. Today, Biocartis offers tests supporting melanoma, colorectal and lung cancer. More information: www.biocartis.com. Press Photo Library available here. Follow us on Twitter: @Biocartis_.

Biocartis and Idylla(TM) are registered trademarks in Europe, the United States and other countries. The Biocartis and Idylla(TM) trademark and logo are used trademarks owned by Biocartis. This press release is not for distribution, directly or indirectly, in any jurisdiction where to do so would be unlawful. Any persons reading this press release should inform themselves of and observe any such restrictions. Biocartis takes no responsibility for any violation of any such restrictions by any person. Please refer to the product labeling for applicable intended uses for each individual Biocartis product. This press release does not constitute an offer or invitation for the sale or purchase of securities in any jurisdiction. No securities of Biocartis may be offered or sold in the United States of America absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933, as amended.

Forward-looking statements

This press release may contain forward-looking statements. Such forward-looking statements are not guarantees of future performance. These forward-looking statements speak only as of the date of this press release. Biocartis expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release, except if specifically required to do so by law or regulation. You should not place undue reliance on forward-looking statements.
HUG#2240606